Anne R Cappola1, Alice M Arnold, Kendra Wulczyn, Michelle Carlson, John Robbins, Bruce M Psaty. 1. Division of Endocrinology, Diabetes and Metabolism (A.R.C., K.W.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104; Department of Biostatistics (A.M.A.), University of Washington, Seattle, Washington ; Department of Mental Health (M.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205; Division of General Medicine (J.R.), University of California, Davis, Sacramento, California 95817; Cardiovascular Health Research Unit (B.M.P.), Departments of Medicine, Epidemiology and Health Services, University of Washington, Seattle, Washington 98101; and Group Health Research Institute (B.M.P.), Group Health Cooperative, Seattle, Washington 98101.
Abstract
CONTEXT: The appropriateness of current reference ranges for thyroid function testing in older adults has been questioned. OBJECTIVE: This study aimed to determine the relationship between thyroid function tests within the euthyroid range and adverse outcomes in older adults not taking thyroid medication. DESIGN, SETTING, AND PARTICIPANTS: US community-dwelling adults years of older (n = 2843) enrolled onto the Cardiovascular Health Study with TSH, free T4 (FT4), and total T3 concentrations in the euthyroid range. MAIN OUTCOME MEASURES: Incidence of atrial fibrillation, coronary heart disease, heart failure, hip fracture, dementia, and all-cause death were measured. RESULTS: No departures from linearity were detected. Higher TSH was negatively associated (P = .03) and higher FT4 was positively associated (P = .007) with mortality. Higher FT4 was associated with atrial fibrillation (P < .001) and heart failure (P = .004). Compared with the first quartile, individuals with TSH in the fourth quartile had a 9.6 per 1000 person-year lower incidence of dementia (P < .05) and those with FT4 in the fourth quartile had higher incidences of atrial fibrillation, coronary heart disease, heart failure, and mortality (11.0, 8.0, 7.8, and 14.3 per 1000 person-years, respectively, all P < .05). Total T3 was not associated with any outcome. CONCLUSIONS: Higher TSH and lower FT4 concentrations within the euthyroid range are associated with lower risk of multiple adverse events in older people, including mortality. This suggests tolerance for lower thyroid hormone levels in this age group. Clinical trials are needed to evaluate the risk-benefit profile of new thresholds for initiating treatment and optimal target concentrations for thyroid hormone replacement in older people.
CONTEXT: The appropriateness of current reference ranges for thyroid function testing in older adults has been questioned. OBJECTIVE: This study aimed to determine the relationship between thyroid function tests within the euthyroid range and adverse outcomes in older adults not taking thyroid medication. DESIGN, SETTING, AND PARTICIPANTS: US community-dwelling adults years of older (n = 2843) enrolled onto the Cardiovascular Health Study with TSH, free T4 (FT4), and total T3 concentrations in the euthyroid range. MAIN OUTCOME MEASURES: Incidence of atrial fibrillation, coronary heart disease, heart failure, hip fracture, dementia, and all-cause death were measured. RESULTS: No departures from linearity were detected. Higher TSH was negatively associated (P = .03) and higher FT4 was positively associated (P = .007) with mortality. Higher FT4 was associated with atrial fibrillation (P < .001) and heart failure (P = .004). Compared with the first quartile, individuals with TSH in the fourth quartile had a 9.6 per 1000 person-year lower incidence of dementia (P < .05) and those with FT4 in the fourth quartile had higher incidences of atrial fibrillation, coronary heart disease, heart failure, and mortality (11.0, 8.0, 7.8, and 14.3 per 1000 person-years, respectively, all P < .05). Total T3 was not associated with any outcome. CONCLUSIONS: Higher TSH and lower FT4 concentrations within the euthyroid range are associated with lower risk of multiple adverse events in older people, including mortality. This suggests tolerance for lower thyroid hormone levels in this age group. Clinical trials are needed to evaluate the risk-benefit profile of new thresholds for initiating treatment and optimal target concentrations for thyroid hormone replacement in older people.
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: D G Ives; A L Fitzpatrick; D E Bild; B M Psaty; L H Kuller; P M Crowley; R G Cruise; S Theroux Journal: Ann Epidemiol Date: 1995-07 Impact factor: 3.797
Authors: Jae Hoon Moon; Young Joo Park; Tae Hui Kim; Ji Won Han; Sung Hee Choi; Soo Lim; Do Joon Park; Ki Woong Kim; Hak Chul Jang Journal: J Clin Endocrinol Metab Date: 2013-11-27 Impact factor: 5.958
Authors: Jacobijn Gussekloo; Eric van Exel; Anton J M de Craen; Arend E Meinders; Marijke Frölich; Rudi G J Westendorp Journal: JAMA Date: 2004-12-01 Impact factor: 56.272
Authors: Peter N Taylor; Ahmed Iqbal; Caroline Minassian; Adrian Sayers; Mohd S Draman; Rosemary Greenwood; William Hamilton; Onyebuchi Okosieme; Vijay Panicker; Sara L Thomas; Colin Dayan Journal: JAMA Intern Med Date: 2014-01 Impact factor: 21.873
Authors: Margaret C Garin; Alice M Arnold; Jennifer S Lee; John Robbins; Anne R Cappola Journal: J Clin Endocrinol Metab Date: 2014-05-30 Impact factor: 5.958
Authors: Oscar L Lopez; Lewis H Kuller; Annette Fitzpatrick; Diane Ives; James T Becker; Norman Beauchamp Journal: Neuroepidemiology Date: 2003 Jan-Feb Impact factor: 3.282
Authors: Carole E Aubert; Carmen Floriani; Douglas C Bauer; Bruno R da Costa; Daniel Segna; Manuel R Blum; Tinh-Hai Collet; Howard A Fink; Anne R Cappola; Lamprini Syrogiannouli; Robin P Peeters; Bjørn O Åsvold; Wendy P J den Elzen; Robert N Luben; Alexandra P Bremner; Apostolos Gogakos; Richard Eastell; Patricia M Kearney; Mari Hoff; Erin Le Blanc; Graziano Ceresini; Fernando Rivadeneira; André G Uitterlinden; Kay-Tee Khaw; Arnulf Langhammer; David J Stott; Rudi G J Westendorp; Luigi Ferrucci; Graham R Williams; Jacobijn Gussekloo; John P Walsh; Drahomir Aujesky; Nicolas Rodondi Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Bjørn O Åsvold; Lars J Vatten; Trine Bjøro; Douglas C Bauer; Alexandra Bremner; Anne R Cappola; Graziano Ceresini; Wendy P J den Elzen; Luigi Ferrucci; Oscar H Franco; Jayne A Franklyn; Jacobijn Gussekloo; Giorgio Iervasi; Misa Imaizumi; Patricia M Kearney; Kay-Tee Khaw; Rui M B Maciel; Anne B Newman; Robin P Peeters; Bruce M Psaty; Salman Razvi; José A Sgarbi; David J Stott; Stella Trompet; Mark P J Vanderpump; Henry Völzke; John P Walsh; Rudi G J Westendorp; Nicolas Rodondi Journal: JAMA Intern Med Date: 2015-06 Impact factor: 21.873
Authors: Maria Papaleontiou; Brittany L Gay; Nazanene H Esfandiari; Sarah T Hawley; Megan R Haymart Journal: Endocr Pract Date: 2016-02-01 Impact factor: 3.443
Authors: Christine Baumgartner; Bruno R da Costa; Tinh-Hai Collet; Martin Feller; Carmen Floriani; Douglas C Bauer; Anne R Cappola; Susan R Heckbert; Graziano Ceresini; Jacobijn Gussekloo; Wendy P J den Elzen; Robin P Peeters; Robert Luben; Henry Völzke; Marcus Dörr; John P Walsh; Alexandra Bremner; Massimo Iacoviello; Peter Macfarlane; Jan Heeringa; David J Stott; Rudi G J Westendorp; Kay-Tee Khaw; Jared W Magnani; Drahomir Aujesky; Nicolas Rodondi Journal: Circulation Date: 2017-10-23 Impact factor: 29.690
Authors: Anne R Cappola; Akshay S Desai; Marco Medici; Lawton S Cooper; Debra Egan; George Sopko; Glenn I Fishman; Steven Goldman; David S Cooper; Samia Mora; Peter J Kudenchuk; Anthony N Hollenberg; Cheryl L McDonald; Paul W Ladenson Journal: Thyroid Date: 2019-05-13 Impact factor: 6.568
Authors: Anne R Cappola; Akshay S Desai; Marco Medici; Lawton S Cooper; Debra Egan; George Sopko; Glenn I Fishman; Steven Goldman; David S Cooper; Samia Mora; Peter J Kudenchuk; Anthony N Hollenberg; Cheryl L McDonald; Paul W Ladenson Journal: Circulation Date: 2019-05-13 Impact factor: 29.690
Authors: Carole E Aubert; Douglas C Bauer; Bruno R da Costa; Martin Feller; Carole Rieben; Eleanor M Simonsick; Kristine Yaffe; Nicolas Rodondi Journal: Clin Endocrinol (Oxf) Date: 2017-09-14 Impact factor: 3.478
Authors: Layal Chaker; Christine Baumgartner; Wendy P J den Elzen; Tinh-Hai Collet; M Arfan Ikram; Manuel R Blum; Abbas Dehghan; Christiane Drechsler; Robert N Luben; Marileen L P Portegies; Giorgio Iervasi; Marco Medici; David J Stott; Robin P Dullaart; Ian Ford; Alexandra Bremner; Anne B Newman; Christoph Wanner; José A Sgarbi; Marcus Dörr; W T Longstreth; Bruce M Psaty; Luigi Ferrucci; Rui M B Maciel; Rudi G Westendorp; J Wouter Jukema; Graziano Ceresini; Misa Imaizumi; Albert Hofman; Stephan J L Bakker; Jayne A Franklyn; Kay-Tee Khaw; Douglas C Bauer; John P Walsh; Salman Razvi; Jacobijn Gussekloo; Henry Völzke; Oscar H Franco; Anne R Cappola; Nicolas Rodondi; Robin P Peeters Journal: J Clin Endocrinol Metab Date: 2016-09-07 Impact factor: 5.958
Authors: Eleanor M Simonsick; Chee W Chia; Jennifer S Mammen; Josephine M Egan; Luigi Ferrucci Journal: J Gerontol A Biol Sci Med Sci Date: 2016-01-20 Impact factor: 6.053